Clinical Trial

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 7, 2024 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations
Trial Details
NCT Number NCT06299371
Lead Sponsor Liaoning Cancer Hospital & Institute
Conditions Non Small Cell Lung Cancer
Enrollment 36 participants
Start Date 2024-04-15
Primary Completion 2026-04-15 (estimated)
Study Completion 2029-04-15 (estimated)
Updated on ClinicalTrials.gov 2024-03-07